[SCHEDULE 13G/A] Zymeworks Inc. SEC Filing
Zymeworks Inc. (ZYME) Schedule 13G/A reports that Redmile Group, LLC and its principal Jeremy C. Green each have shared voting and dispositive power over 4,150,627 shares of Zymeworks common stock, representing 5.6% of the class based on 74,844,505 shares outstanding as of June 27, 2025. One Redmile vehicle, Redmile Biopharma Investments III, L.P., holds 3,470,727 shares ( 4.6%). The filers state the shares are held by Redmile-managed private investment vehicles, that Redmile and Mr. Green may be deemed beneficial owners solely as manager/principal, and they disclaim beneficial ownership except to the extent of any pecuniary interest. The filing certifies the securities were acquired and are held in the ordinary course of business and not to change or influence control.
Zymeworks Inc. (ZYME) nel Schedule 13G/A segnala che Redmile Group, LLC e il suo principale Jeremy C. Green hanno ciascuno poteri di voto e dispositivi condivisi su 4.150.627 azioni ordinarie di Zymeworks, pari al 5,6% della classe sulla base di 74.844.505 azioni in circolazione al 27 giugno 2025. Un veicolo di Redmile, Redmile Biopharma Investments III, L.P., detiene 3.470.727 azioni ( 4,6%). I dichiarante precisano che le azioni sono detenute da veicoli d'investimento privati gestiti da Redmile, che Redmile e il sig. Green possono essere considerati proprietari benefici solo in qualit脿 di gestore/principale, e declinano la titolarit脿 beneficiaria eccetto nella misura di eventuali interessi pecuniari. La comunicazione certifica che i titoli sono stati acquisiti e sono detenuti nell'ordinaria attivit脿 d'impresa e non per modificare o influenzare il controllo.
Zymeworks Inc. (ZYME) en el Schedule 13G/A informa que Redmile Group, LLC y su principal Jeremy C. Green tienen, cada uno, poder compartido de voto y disposici贸n sobre 4.150.627 acciones ordinarias de Zymeworks, lo que representa el 5,6% de la clase sobre la base de 74.844.505 acciones en circulaci贸n a 27 de junio de 2025. Un veh铆culo de Redmile, Redmile Biopharma Investments III, L.P., posee 3.470.727 acciones ( 4,6%). Los declarante indican que las acciones est谩n en veh铆culos de inversi贸n privados gestionados por Redmile, que Redmile y el Sr. Green pueden considerarse propietarios beneficiarios 煤nicamente como gestor/principal, y renuncian a la titularidad beneficiaria salvo en la medida de cualquier inter茅s pecuniario. El informe certifica que los valores se adquirieron y se mantienen en el curso ordinario del negocio y no para cambiar o influir en el control.
Zymeworks Inc. (ZYME)鞚� Schedule 13G/A電� Redmile Group, LLC鞕� 攴� 毂呾瀯鞛� Jeremy C. Green臧� 臧侁皝 Zymeworks 氤错喌欤� 4,150,627欤检棎 雽�頃� 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓岇潉 氤挫湢頃橁碃 鞛堨溂氅�, 鞚措姅 2025雲� 6鞗� 27鞚� 旮办 氚滍枆欤检嫕 74,844,505欤茧ゼ 旮办鞙茧 齑濎＜鞁濎潣 5.6%鞐� 頃措嫻頃滊嫟瓿� 氤搓碃頃╇媹雼�. Redmile鞚� 頃� 韴瀽 靾橂嫧鞚� Redmile Biopharma Investments III, L.P.電� 3,470,727欤�( 4.6%)毳� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 鞝滌稖鞚鸽摛鞚� 頃措嫻 欤检嫕鞚� Redmile鞚� 鞖挫毄頃橂姅 靷 韴瀽 旮瓣惮鞐� 鞚橅暣 氤挫湢霅橁碃 鞛堨溂氅�, Redmile瓿� Mr. Green鞚� 甏�毽瀽/雽�響滊靹滊 鞁れ鞝� 靻岇湢鞛愲 臧勳＜霅� 靾� 鞛堦碃, 旮堨爠鞝� 鞚挫澋鞚� 鞛堧姅 瓴届毎毳� 鞝滌櫢頃橁碃電� 鞁れ鞝� 靻岇湢毳� 攵�鞚疙暅雼り碃 氚濏灆雼堧嫟. 鞝滌稖靹滊電� 頃措嫻 歃濌秾鞚� 韱奠儊鞝侅澑 鞓侅梾頇滊彊 瓿检爼鞐愳劀 旆摑路氤挫湢霅� 瓴冹澊氅� 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼鞚� 氙胳箻霠る姅 氇╈爜鞚� 鞎勲嫎鞚� 頇曥澑頃╇媹雼�.
Zymeworks Inc. (ZYME) d茅clare dans le Schedule 13G/A que Redmile Group, LLC et son principal Jeremy C. Green d茅tiennent chacun un pouvoir de vote et de disposition partag茅 sur 4 150 627 actions ordinaires de Zymeworks, repr茅sentant 5,6 % de la cat茅gorie sur la base de 74 844 505 actions en circulation au 27 juin 2025. Un v茅hicule de Redmile, Redmile Biopharma Investments III, L.P., d茅tient 3 470 727 actions ( 4,6 %). Les d茅clarants indiquent que les actions sont d茅tenues par des v茅hicules d'investissement priv茅s g茅r茅s par Redmile, que Redmile et M. Green ne peuvent 锚tre consid茅r茅s comme propri茅taires b茅n茅ficiaires que comme gestionnaire/principal, et qu'ils d茅clinent la qualit茅 de propri茅taire b茅n茅ficiaire sauf dans la mesure d'un int茅r锚t p茅cuniaire 茅ventuel. Le d茅p么t certifie que les titres ont 茅t茅 acquis et sont d茅tenus dans le cours normal des affaires et non dans le but de modifier ou d'influencer le contr么le.
Zymeworks Inc. (ZYME) meldet im Schedule 13G/A, dass Redmile Group, LLC und deren Hauptvertreter Jeremy C. Green jeweils gemeinschaftliche Stimm- und Verf眉gungsrechte 眉ber 4.150.627 Aktien der Zymeworks-Stammaktien halten, was basierend auf 74.844.505 ausstehenden Aktien zum 27. Juni 2025 5,6% der Klasse entspricht. Ein Redmile-Fahrzeug, Redmile Biopharma Investments III, L.P., h盲lt 3.470.727 Aktien ( 4,6%). Die Einreicher geben an, dass die Aktien von privat verwalteten Investmentvehikeln unter Redmile gehalten werden, dass Redmile und Herr Green allenfalls als Manager/Principal als wirtschaftliche Eigent眉mer angesehen werden k枚nnen und sie das wirtschaftliche Eigentum au脽er im Umfang eines etwaigen pecuni盲ren Interesses verneinen. Die Meldung best盲tigt, dass die Wertpapiere im gew枚hnlichen Gesch盲ftsbetrieb erworben und gehalten werden und nicht dazu dienen, die Kontrolle zu 盲ndern oder zu beeinflussen.
- Transparent disclosure of share counts and percent of class (4,150,627 shares; 5.6% of class)
- Clear allocation of holdings across entities including Redmile Biopharma Investments III, L.P. (3,470,727 shares; 4.6%)
- Certification that shares were acquired and are held in the ordinary course of business
- None.
Insights
TL;DR: Redmile reports a disclosed passive stake of 5.6% in Zymeworks, held through managed vehicles; no sole voting or dispositive power.
Redmile Group, LLC and Jeremy C. Green report shared voting and dispositive power over 4,150,627 shares, representing 5.6% of outstanding common stock, while Redmile Biopharma Investments III, L.P. holds 3,470,727 shares (4.6%). The filing follows Schedule 13G/A conventions for passive investors and includes standard disclaimers that beneficial ownership is only to the extent of pecuniary interest. From a market-impact perspective, a disclosed stake above 5% is material in size but the certification that holdings are in the ordinary course and not for influencing control suggests a passive intent. All figures are explicitly stated in the filing.
TL;DR: Filing documents managerial control over shares via investment vehicles and includes appropriate disclaimers; no indication of active control.
The disclosure clarifies that Redmile Group, LLC acts as investment manager for the Redmile Clients and that Jeremy C. Green is the principal of Redmile Group, LLC, which may lead to deemed beneficial ownership under SEC rules. The report shows shared voting and dispositive power, with no sole voting or disposition power reported. The signature and certification language confirm the holders assert ordinary-course, non-control motives. This is consistent with a passive investor Schedule 13G/A rather than a Schedule 13D activist filing.
Zymeworks Inc. (ZYME) nel Schedule 13G/A segnala che Redmile Group, LLC e il suo principale Jeremy C. Green hanno ciascuno poteri di voto e dispositivi condivisi su 4.150.627 azioni ordinarie di Zymeworks, pari al 5,6% della classe sulla base di 74.844.505 azioni in circolazione al 27 giugno 2025. Un veicolo di Redmile, Redmile Biopharma Investments III, L.P., detiene 3.470.727 azioni ( 4,6%). I dichiarante precisano che le azioni sono detenute da veicoli d'investimento privati gestiti da Redmile, che Redmile e il sig. Green possono essere considerati proprietari benefici solo in qualit脿 di gestore/principale, e declinano la titolarit脿 beneficiaria eccetto nella misura di eventuali interessi pecuniari. La comunicazione certifica che i titoli sono stati acquisiti e sono detenuti nell'ordinaria attivit脿 d'impresa e non per modificare o influenzare il controllo.
Zymeworks Inc. (ZYME) en el Schedule 13G/A informa que Redmile Group, LLC y su principal Jeremy C. Green tienen, cada uno, poder compartido de voto y disposici贸n sobre 4.150.627 acciones ordinarias de Zymeworks, lo que representa el 5,6% de la clase sobre la base de 74.844.505 acciones en circulaci贸n a 27 de junio de 2025. Un veh铆culo de Redmile, Redmile Biopharma Investments III, L.P., posee 3.470.727 acciones ( 4,6%). Los declarante indican que las acciones est谩n en veh铆culos de inversi贸n privados gestionados por Redmile, que Redmile y el Sr. Green pueden considerarse propietarios beneficiarios 煤nicamente como gestor/principal, y renuncian a la titularidad beneficiaria salvo en la medida de cualquier inter茅s pecuniario. El informe certifica que los valores se adquirieron y se mantienen en el curso ordinario del negocio y no para cambiar o influir en el control.
Zymeworks Inc. (ZYME)鞚� Schedule 13G/A電� Redmile Group, LLC鞕� 攴� 毂呾瀯鞛� Jeremy C. Green臧� 臧侁皝 Zymeworks 氤错喌欤� 4,150,627欤检棎 雽�頃� 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓岇潉 氤挫湢頃橁碃 鞛堨溂氅�, 鞚措姅 2025雲� 6鞗� 27鞚� 旮办 氚滍枆欤检嫕 74,844,505欤茧ゼ 旮办鞙茧 齑濎＜鞁濎潣 5.6%鞐� 頃措嫻頃滊嫟瓿� 氤搓碃頃╇媹雼�. Redmile鞚� 頃� 韴瀽 靾橂嫧鞚� Redmile Biopharma Investments III, L.P.電� 3,470,727欤�( 4.6%)毳� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 鞝滌稖鞚鸽摛鞚� 頃措嫻 欤检嫕鞚� Redmile鞚� 鞖挫毄頃橂姅 靷 韴瀽 旮瓣惮鞐� 鞚橅暣 氤挫湢霅橁碃 鞛堨溂氅�, Redmile瓿� Mr. Green鞚� 甏�毽瀽/雽�響滊靹滊 鞁れ鞝� 靻岇湢鞛愲 臧勳＜霅� 靾� 鞛堦碃, 旮堨爠鞝� 鞚挫澋鞚� 鞛堧姅 瓴届毎毳� 鞝滌櫢頃橁碃電� 鞁れ鞝� 靻岇湢毳� 攵�鞚疙暅雼り碃 氚濏灆雼堧嫟. 鞝滌稖靹滊電� 頃措嫻 歃濌秾鞚� 韱奠儊鞝侅澑 鞓侅梾頇滊彊 瓿检爼鞐愳劀 旆摑路氤挫湢霅� 瓴冹澊氅� 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼鞚� 氙胳箻霠る姅 氇╈爜鞚� 鞎勲嫎鞚� 頇曥澑頃╇媹雼�.
Zymeworks Inc. (ZYME) d茅clare dans le Schedule 13G/A que Redmile Group, LLC et son principal Jeremy C. Green d茅tiennent chacun un pouvoir de vote et de disposition partag茅 sur 4 150 627 actions ordinaires de Zymeworks, repr茅sentant 5,6 % de la cat茅gorie sur la base de 74 844 505 actions en circulation au 27 juin 2025. Un v茅hicule de Redmile, Redmile Biopharma Investments III, L.P., d茅tient 3 470 727 actions ( 4,6 %). Les d茅clarants indiquent que les actions sont d茅tenues par des v茅hicules d'investissement priv茅s g茅r茅s par Redmile, que Redmile et M. Green ne peuvent 锚tre consid茅r茅s comme propri茅taires b茅n茅ficiaires que comme gestionnaire/principal, et qu'ils d茅clinent la qualit茅 de propri茅taire b茅n茅ficiaire sauf dans la mesure d'un int茅r锚t p茅cuniaire 茅ventuel. Le d茅p么t certifie que les titres ont 茅t茅 acquis et sont d茅tenus dans le cours normal des affaires et non dans le but de modifier ou d'influencer le contr么le.
Zymeworks Inc. (ZYME) meldet im Schedule 13G/A, dass Redmile Group, LLC und deren Hauptvertreter Jeremy C. Green jeweils gemeinschaftliche Stimm- und Verf眉gungsrechte 眉ber 4.150.627 Aktien der Zymeworks-Stammaktien halten, was basierend auf 74.844.505 ausstehenden Aktien zum 27. Juni 2025 5,6% der Klasse entspricht. Ein Redmile-Fahrzeug, Redmile Biopharma Investments III, L.P., h盲lt 3.470.727 Aktien ( 4,6%). Die Einreicher geben an, dass die Aktien von privat verwalteten Investmentvehikeln unter Redmile gehalten werden, dass Redmile und Herr Green allenfalls als Manager/Principal als wirtschaftliche Eigent眉mer angesehen werden k枚nnen und sie das wirtschaftliche Eigentum au脽er im Umfang eines etwaigen pecuni盲ren Interesses verneinen. Die Meldung best盲tigt, dass die Wertpapiere im gew枚hnlichen Gesch盲ftsbetrieb erworben und gehalten werden und nicht dazu dienen, die Kontrolle zu 盲ndern oder zu beeinflussen.
FAQ
How many ZYME shares does Redmile Group, LLC report beneficially owning?
What stake does Redmile Biopharma Investments III, L.P. hold in Zymeworks (ZYME)?
Does Redmile or Jeremy C. Green report sole voting or dispositive power over the shares?
Does the filing state the intent to influence control of Zymeworks?
On what outstanding share count are the percentages based?
